Overview

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Status:
Completed

Trial end date:
2007-09-24

Target enrollment:
0

Participant gender:
All

Summary

This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.
Vyne Therapeutics Inc.

Criteria

Inclusion Criteria:

- Patients with predominantly urge incontinence overactive bladder episodes

- Patients must meet minimum eligibility requirements (e.g., average number of
micturitions/day) based on screening diary cards

Exclusion Criteria:

- History of Diabetes insipidus, uncontrolled hyperglycemia or hypercalcemia

- Lower urinary tract symptoms associated with benign prostatic hypertrophy

- Active or current Urinary Tract Infections (UTIs)

- Surgery to correct prolapsed uterus or stress incontinence